The present invention is directed to compositions including the cytokines IL-18 and IL-22 or biologically active fragments or variants thereof. In some embodiments, the compositions further include a pharmaceutically acceptable carrier. The compositions can further include other interleukins such as IL-1β, and IL 1β can be used as a combination therapy with either IL-18 or IL-22 or biologically active fragments or variants thereof.
